Imbrium Therapeutics

Imbrium Therapeutics, founded in 2019 as an operating subsidiary of Purdue Pharma, is committed to applying its capabilities in science and medicine to rapidly advance the development of new, favorably differentiated therapeutic agents in the fields of oncology, central nervous system, and non-opioid pain. With its unique mission, focused therapeutic areas, and leadership team, Imbrium Therapeutics is dedicated to operating ethically and in full compliance with the laws and regulations governing the pharmaceutical industry.